Conyngham Launches Gamgee AI Cancer Vaccine Startup
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Paul Conyngham launched Gamgee to offer personalized mRNA cancer vaccines for dogs, backed by Y Combinator, with ambitions extending to humans and other species.
- The startup's origin story centers on Rosie, Conyngham's Staffordshire bull terrier-Shar Pei mix, whose tumors he says shrank after a vaccine he designed using ChatGPT and computational genomics — though Conyngham stresses on the company's website that he is "not a biologist."
- Researchers told The Verge the science behind Rosie's case was messier than Conyngham's account suggests: the exact role of AI was unclear, and Rosie received the mRNA vaccine alongside another therapy, making it impossible to attribute her improvement to the vaccine alone.
- Gamgee is recruiting for its first clinical trials in Australia and accepting cases globally, touting roughly 75% tumor reduction in its "first documented case," under 20 minutes of a veterinarian's time, and a finished vaccine in around four weeks.
- The company says it is collaborating with the University of Queensland and institutes at the University of New South Wales, and is encouraging funders and study partners to reach out.
Why it matters: Gamgee is commercializing a single dog's story whose causal link to the treatment at the core of its pitch is unproven — the protocol made clean attribution impossible, per researchers cited by The Verge. With Y Combinator backing, university collaborations, and a global waitlist already open, the gap between the marketing narrative and the underlying science is now a fundraising and clinical-trial question, not just a media one.
Ask SkimNews
